EP Patent

EP3209647B1 — Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidine-2,4-diamine

Assigned to Ariad Pharmaceuticals Inc · Expires 2020-06-03 · 6y expired

What this patent protects

Patent listed against Alunbrig.

Drugs covered by this patent

Patent Metadata

Patent number
EP3209647B1
Jurisdiction
EP
Classification
—
Expires
2020-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.